Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: A Japanese experience

Japanese Journal of Clinical Oncology

Volumn 37, Issue 3, 2007, Pages 201-206

  Akaza, Hideyuki ^a   Naito, Seiji ^b   Usami, Michiyuki ^c   Miki, Tsuneharu ^d   Miyanaga, Naoto ^a   Taniai, Hisashi ^e  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder cancer; Cisplatin resistance; Gemcitabine; Second line chemotherapy; Transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NEDAPLATIN; UFT; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INJECTION SITE REACTION; JAPAN; LEUKOPENIA; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; WEIGHT REDUCTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 34447634926     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym011     Document Type: Article

References (27)

1. Torii T, Akaza H. Transitional cell carcinoma of the urothelium. In: Clinical Oncology, 3rd edn. Japan Society of Medical Oncology. Tokyo: Cancer and Chemotherapy Publishers 2003;749-70 (in Japanese).
2. Miyanaga N, Akaze H. Bladder cancer. Nippon-Rinsho 2001;59 (Suppl 7):379-85 (in Japanese).
3. Miyanaga N, Tsukamoto S, Hattori K, Kawai K, Shimizu T, Akaza H, et al. Chemotherapy and radiotherapy for mological cancer. Jpn J Cancer Chemother 2002;29:709-716 (in Japanese).
4. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Moore MJ, Bodrogi I, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
5. Kaufman D, Raghavan D, Carducci M, Carducci M, Levine G, Murphy B, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;17:1921-7.
6. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
7. Rosenberg JE, Carroll PR, Small EJ. Update of chemotherapy for advanced bladder cancer. J Urol 2005;174:14-20.
8. von der Maase H. Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit Rev Oncol Hematol 2000;34:175-84.
9. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998;34:1208-1.
10. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced mothelial carcinoma. J Clin Oncol 1997;15:589-93.
11. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-7.
12. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-40.
13. Kuroda M, Kotake T, Akaza H, Hinotsu H, Kakizoe T, et al. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: A prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Jpn J Clin Oncol 1998;28:497-501.
14. Loehrer PJ, Sr, Einhorn LH, Elson PJ, Crawford ED, Kuchler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10:1066-73.
15. von der Maase. Gemcitabine-containing regimens in bladder cancer: A new standard of care. Sem Oncol 2001;28(Suppl 10):1-3.
16. Koga H, Naito S. Recent progress in the treatment for urothelial cancer. Jpn J Cancer Chemother 2006;33:164-70 (in Japanese).
17. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14-20.
18. Shipley WU, Kaufman DS, McDougal WS, Dahl DM, Michaelson MD, Zeitman AL. Cancer of the bladder, ureter, and renal pelvis. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles Practice of Oncology, 7th edn. Philadelphia, PA: Lippincott, Williams and Wilkins 2004; 1168-85.
19. Montie J, Abrahams N, Bahnson R, Eisenberger M, El-Galley R, Herr H, et al. Bladder Cancer: NCCN Clinical Practice Guidelines in Oncology, vol. 1 [homepage on the Internet]. Pennsylvania: National Comprehensive Cancer Network [updated 20 March 2006; cited 26 July 2006]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf
20. Fukuoka M, Negoro S, Kudo S, Furuse K, Nishikawa H, Takada Y, et al. Gemcitabine late phase II cooperative study group A. Jpn J Cancer Chemother 1996;23:1825-32 (in Japanese).
21. Yokoyama A, Nakai Y, Yoneda S, Kurita Y, Niitani H, Taguchi T. Gemcitabine cooperative study group B for late phase II. Jpn J Cancer Chemother 1996;23:1681-8 (in Japanese).
22. Okada S, Ueno H, Okusaka, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
23. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006;57:647-53.
24. Yamamoto N. Non-small-cell lung cancer a) Internal medicine. In: Clinical Oncology, 3rd edn. Japan Society of Medical Oncology. Tokyo: Cancer and Chemotherapy Publishers 2003; 535-60 (in Japanese).
25. Kurita Y, Yokoyama A, Matsui K, Hara N, Nakai Y, Ohashi Y, et al. Phase I study of gemcitabine hydrochloride (LY188011) combination therapy with cisplatin in the patients with non-small-cell lung cancer. Jpn J Cancer Chemother 1999;26:898-907 (in Japanese).
26. Kunikane H, Kurita Y, Watanabe K, Yokoyama A, Noda K, Fujita Y, et al. A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in no-small-cell lung cancer: 3-week schedule. Int J Clin Oncol 2001;6:284-90.
27. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Tamura T, Negor S, et al. The four arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol, [2004 ASCO Annual Meeting Proceedings (post-meeting edition)] 2004;22(No. 14 Suppl):7006.